(Q34654433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

HIV entry inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9581

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

81-88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of viral membrane fusion and its inhibition

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Virus entry as a target for anti-HIV intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Enfuvirtide, a new drug for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Retrovirus meeting. Hope on new AIDS drugs, but breast-feeding strategy backfires

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

GlaxoSmithKline ends aplaviroc trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Biology of CCR5 and its role in HIV infection and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Successful desensitization of enfuvirtide after a first attempt failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV co-receptor inhibitors as novel class of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Novel therapies based on mechanisms of HIV-1 cell entry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

HIV-resistance to viral entry inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Assessing chemokine co-receptor usage in HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

The case for selection at CCR5-Delta32

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

CCR5 deficiency decreases susceptibility to experimental cerebral malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

CCR5 deficiency increases risk of symptomatic West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

CC chemokine receptor 5 and renal-transplant survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

The bicyclam AMD3100 story

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961052-6

7 January 2021

10.1016/S0140-6736(07)61052-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17617275%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference